BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 13, 2025
See today's BioWorld Asia
Home
» Prosonix Adds New Investor, Raises $9M for Inhaled Drugs
To read the full story,
subscribe
or
sign in
.
Prosonix Adds New Investor, Raises $9M for Inhaled Drugs
May 23, 2012
By
Nuala Moran
LONDON – Particle engineering specialist Prosonix Ltd. has raised a further £5.7 million (US$9 million) in a second closing of Series B funding, taking the total for the round to £17.1 million.
BioWorld Asia